(20R)-Panaxadiol as a Natural Active Component with Anti-Obesity Effects on ob/ob Mice via Modulating the Gut Microbiota

Molecules. 2022 Apr 13;27(8):2502. doi: 10.3390/molecules27082502.

Abstract

Obesity is an important cause of diseases such as type 2 diabetes, non-alcoholic fatty liver and atherosclerosis. The use of ingredients extracted from traditional Chinese medicine for weight loss is now receiving more and more attention. Ginseng has been recorded since ancient times for the treatment of diabetes. The (20R)-Panaxadiol (PD) belongs to the ginseng diol type compounds, which are moderately bioavailable and may remain in the intestinal tract for a longer period of time. This study investigated the potential positive effect of PD in ob/ob mice and evaluated its effect against obesity. The ob/ob mice were administered PD for ten weeks. Our study showed that PD could improve obesity, glucose tolerance disorder, as well as gut dysbiosis. Panaxadiol decreased ob/ob mice's Firmicutes/Bacteroidetes (F/B). Furthermore, 16S rRNA gene sequencing of the fecal microbiota suggested that PD changed the composition of the gut microbiota in ob/ob mice and modulated specific bacteria such as lactobacillus, prevotellace and so on. Moreover, PD improved the intestinal wall integrity. In conclusion, our results suggest that (20R)-Panaxadiol, as an active ingredient of the traditional Chinese medicinal herb ginseng, may improve obesity to some extent via improving gut microbiota.

Keywords: (20R)-Panaxadiol; gut microbiota; obesity.

MeSH terms

  • Animals
  • Diabetes Mellitus, Type 2* / complications
  • Diet, High-Fat
  • Gastrointestinal Microbiome*
  • Ginsenosides
  • Mice
  • Mice, Inbred C57BL
  • Obesity / etiology
  • Panax*
  • RNA, Ribosomal, 16S / genetics

Substances

  • Ginsenosides
  • RNA, Ribosomal, 16S
  • panaxadiol